Liposomal bupivacaine during subcutaneous implantable cardioverter defibrillator implantation for pain management.
Abhishek J DeshmukhAmy E GlasgowElizabeth B HabermannLuis ScottWin-Kuang ShenFred M KusumotoChristopher J McLeodVasudha GoelPranita KagineleYong Mei ChaM P H Paul A FriedmanSamuel J AsirvathamSiva K MulpuruPublished in: Pacing and clinical electrophysiology : PACE (2021)
Intraprocedural liposomal bupivacaine administration was not associated with any significant impact on postoperative pain scores, inpatient opioid administration, and outpatient opioid prescription rates or OME amounts at discharge.